Empagliflozin in heart failure without diabetes

The effect of different doses of empagliflozin on quality of life, heart function, atherosclerosis, vascular inflammation, blood pressure and lipid profile in non-diabetic patients with heart failure

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210828052313N1

Enrollment

300

Registered

2022-06-13

Start date

2021-11-21

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure. Heart failure

Interventions

Intervention group: A group of 150 people is given 10 mg of empagliflozin every night for one year.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 35<EF<50

Exclusion criteria

Exclusion criteria: DM GFR<30

Design outcomes

Primary

Measure	Time frame
Ejection fraction. Timepoint: At the beginning of the study and 6 months after starting the drug. Method of measurement: Echocardiography.;Quality of life. Timepoint: At the beginning of the study and 6 months after starting the drug. Method of measurement: kansas city cardiomyopathy questionnaire.	—

Secondary

Measure	Time frame
Laboratory finding. Timepoint: The beginning of the study and six months after starting the medication. Method of measurement: Laboratory measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Fatemian

Shiraz University of Medical Sciences

hoseinfatemian@yahoo.com+98 71 3636 1088

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026